QTc shortening with a new investigational cancer drug: A brief case study

Journal of Pharmacological and Toxicological Methods

Volumn 62, Issue 1, 2010, Pages 72-81

  Himmel, Herbert M ^a   Hoffmann, Michael ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Anesthetized dog; Electrophysiological methods; HERG potassium current; ICH S7B; QT interval; Rabbit Langendorff heart

Indexed keywords

BAY 79; POTASSIUM CHANNEL HERG; POTASSIUM ION; PROTEIN TYROSINE KINASE INHIBITOR; SODIUM CHANNEL NAV1.5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOLATED HEART; MALE; NONHUMAN; POTASSIUM CURRENT; PURKINJE FIBER MEMBRANE POTENTIAL; QRS COMPLEX; QT INTERVAL; RABBIT; RISK BENEFIT ANALYSIS; TOXICITY TESTING;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; HEART; HEK293 CELLS; HUMANS; MALE; MUSCLE PROTEINS; ORGANIC CHEMICALS; PROTEIN KINASE INHIBITORS; PURKINJE FIBERS; RABBITS; SODIUM CHANNELS;

CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 77956175181     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2010.05.012     Document Type: Article

References (42)

1. Anderson M.E. Multiple downstream proarrhythmic targets for calmodulin kinase II: Moving beyond an ion channel-centric focus. Cardiovascular Research 2007, 73:657-666.
2. Anon. (2005). ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. CHMP/ICH/423/02. http://www.ich.org/cache/compo/276-254-1.html.
3. Bazett H.C. An analysis of the time-relations of electrocardiograms. Heart 1920, 7:353-370.
4. Bellocq C., van Ginneken A.C., Bezzina C.R., Alders M., Escande D., Mannens M.M.A.M., et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004, 109:2394-2397.
5. Borggrefe M., Wolpert C., Antzelevitch C., Veltmann C., Giustetto C., Gaita F., et al. Short QT syndrome. Genotype-phenotype correlations. Journal of Electrocardiology 2005, 38:75-80. Suppl.
6. + current by src tyrosine kinase. Journal of Biological Chemistry 2002, 277:13673-13681.
7. Cheng T.O. Digitalis administration: An underappreciated but common cause of short QT interval. Circulation 2004, 109:e152.
8. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annual Reviews in Pharmacology and Toxicology 2003, 43:441-461.
9. Extramiana F., Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular wedge model of short QT syndrome. Circulation 2004, 110:3661-3666.
10. Force T., Kerkelä R. Cardiotoxicity of the new cancer therapeutics - Mechanisms of, and approaches to, the problem. Drug Discovery Today 2008, 13:778-784.
11. Force T., Krause D.S., van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 2007, 7:332-344.
12. Ks channels by HMR 1556. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 362:480-488.
13. Guo D., Zhao X., Wu Y., Liu T., Kowey P.R., Yan G. L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation. Journal of Cardiovascular Electrophysiology 2007, 18:196-203.
14. Hamill O.P., Marty A., Neher E., Sakmann B., Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfluegers Archives 1981, 391:85-100.
15. Hansen R.S., Diness T.G., Christ T., Demnitz J., Ravens U., Olesen S.P., et al. Activation of human ether-a-go-go-related gene potassium channels by diphenylurea 1, 3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643). Molecular Pharmacology 2006, 69:266-277.
16. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S., Rampe D., Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological and Toxicological Methods 2006, 54:116-129.
17. Hanton G., Nahas K., Priou C., Rabemampianina Y., Baneux P. The QT interval in the dog ECG: Importance in preclinical toxicology and relationship to heart rate. Toxicology Methods 2001, 11:21-40.
18. Himmel H.M. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential. Journal of Pharmacological and Toxicological Methods 2007, 56:145-158.
19. Hoffmann P., Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis ? A review of emerging trends. Journal of Pharmacological and Toxicological Methods 2006, 53:87-105.
20. Holbrook M., Malik M., Shah R.R., Valentin J.P. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development ?. Journal of Pharmacological and Toxicological Methods 2009, 59:21-28.
21. Hondeghem L.M. Relative contributions of TRIaD and QT to proarrhythmia. Journal of Cardiovascular Electrophysiology 2007, 18:655-657.
22. Hondeghem L.M., Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology 2003, 41:14-24.
23. Kang J., Chen X.L., Wang H., Ji J., Cheng H., Incardona J., et al. Discovery of a small molecule activator of the human ether-a-go-go-related gene (hERG) cardiac K channel. Molecular Pharmacology 2005, 67:827-836.
24. Karjalainen J., Viitasalo M. Fever and cardiac rhythm. Archives of Internal Medicine 1986, 146:1169-1171.
25. Lawrence C.L., Bridgland-Taylor M.H., Pollard C.E., Hammond T.G., Valentin J.P. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes. British Journal of Pharmacology 2006, 149:845-860.
26. + currents. Circulation Research 2006, 99:1092-1099.
27. Lu H.R., Vlaminckx E., Hermans A.N., Rohrbacher J., van Ammel K., Towart R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. British Journal of Pharmacology 2008, 154:1427-1438.
28. Malik M. Facts, fancies and follies of drug-induced QT/QTc interval shortening. British Journal of Pharmacology 2010, 159:70-76.
29. Nierenberg D.W., Ransil B.J. Q-aTc interval as a clinical indicator of hypercalcemia. American Journal of Cardiology 1979, 44:243-248.
30. Pollard C.E., Abi Gerges N., Bridgland-Taylor M.H., Easter A., Hammond T.G., Valentin J.P. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. British Journal of Pharmacology 2010, 159:12-21.
31. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de Pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 2003, 58:32-45.
32. + currents. Molecular Pharmacology 1998, 53:220-230.
33. Shah R.R. Drug-induced QT interval shortening: Potential harbinger of proarrhythmia and regulatory perspectives. British Journal of Pharmacology 2010, 159:58-69.
34. Strevel E.L., Ing D.J., Siu L.L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. Journal of Clinical Oncology 2007, 25:3362-3371.
35. Tattersall M.L., Dymond M., Hammond T., Valentin J.P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. Journal of Pharmacological and Toxicological Methods 2006, 53:11-19.
36. Valentin J.P., Hoffmann P., de Clerck F., Hammond T.G., Hondeghem L.M. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. Journal of Pharmacological and Toxicological Methods 2004, 49:171-181.
37. Van de Water A., Verheyen J., Xhonneux R., Reneman R.S. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. Journal of Pharmacological Methods 1989, 22:207-217.
38. Vormberge T., Hoffmann M., Himmel H.M. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. Journal of Pharmacological and Toxicological Methods 2006, 54:130-140.
39. Weiss D.L., Seemann G., Sachse F.B., Dössel O. Modelling of short QT syndrome in a heterogenous model of the human ventricular wall. Europace 2005, 7:S105-S117.
40. Wolpert C., Schimpf R., Veltmann C., Giustetto C., Gaita F., Borggrefe M. Clinical characteristics and treatment of short QT syndrome. Expert Reviews in Cardiovascular Therapy 2005, 3:611-617.
41. Zhou J., Augelli-Szafran C.E., Bradley J.A., Chen X., Koci B.J., Volberg W.A., et al. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in-vitro antiarrhythmic activity. Molecular Pharmacology 2005, 68:876-884.
42. Zhou Z.F., Gong Q., Ye B., Fan Z., Makielski J.C., Robertson G.A., et al. Properties of hERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophysical Journal 1998, 74:230-241.